Just kicking the tires here. Dew - I understand what you are saying with regards to RT002 having the best potential here and that RT001 should not have been a priority in the first place. However, I assume that the company had prioritized RT001 ahead of RT002 for reasons that is inconsistent with RT002 having better clinical potential. Why did the company do that in your view? Until I understand that, it is hard for me to be excited about anything that the company does.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.